Tonix Pharmaceuticals Holding Corp, plans to open new manufacturing facility. The new R&D facility will address Advanced Development Center (ADC) for vaccine programs.
The new Advanced Development Center (ADC) will support research, development and analytical capabilities which also includes the production of quality trial vaccines for infectious diseases such as COVID-19.
The Advanced Development Center (ADC),comprises of single-use bioreactors and purification suites. Moreover when the facility becomes fully operational, Good Manufacturing Practice (GMP) production of vaccines for clinical trialswill have the capacity to produce sterile vaccines in glass bottles.
The facility is expected to hire 70 employees including scientists, researchers, manufacturing and technical support staff.
The construction of the site has begun and expected to be fully operational in first half of 2022.